Tag: ALSFRS-R
Zydus Lifesciences completes Phase II(a) clinical trial of Usnoflast in ALS...
Usnoflast, a novel oral NLRP3 inflammasome inhibitor, shows promising results in reducing neurodegeneration and improving key health markers